Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Eli Lilly and Company director Mary Lynne Hedley reported acquiring additional common stock of LLY. On 11/17/2025, she acquired 9.706 shares of common stock and a separate 215.327-share award, both shown as acquisitions. The filing shows she beneficially owns 2,240.861 shares directly after these transactions, plus 98 shares held indirectly by a trust. According to the disclosure, the shares in one row were deferred in lieu of cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after she separates from service.
Eli Lilly & Co. director reports additional stock units from fee deferral
A director of Eli Lilly & Co. (LLY) reported acquiring small amounts of common stock on 11/17/2025, shown as 9.706 and 215.327 shares, through transactions coded as acquisitions. According to the explanation, these amounts represent fees that the director elected to defer in the form of stock units under the Lilly Directors' Deferral Plan instead of taking cash compensation. The filing states these deferred stock units will be settled in shares of common stock after the director separates from service. Following these transactions, the director’s beneficial ownership is listed as 74,988.689 shares held directly.
Eli Lilly & Co (LLY) director Katherine Baicker reported a new stock purchase. On 11/17/2025, she acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. Following this transaction, she directly beneficially owns 23,502.628 shares of Eli Lilly common stock.
Eli Lilly & Co. director Ralph Alvarez reported acquiring additional common stock in the company. On 11/17/2025, he acquired 11.5 shares and 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share in two separate transactions. Following these transactions, Alvarez directly beneficially owns 55,378.773 shares of common stock and indirectly owns 758 shares through a trust. Some of the acquired shares were deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after he separates from board service, aligning a portion of his director compensation with the company’s equity performance.
Lilly Endowment Inc., a 10% owner of Eli Lilly and Company (LLY), reported open-market sales of common stock. On November 17, 2025, it sold 7,789 shares at a weighted average price of $1,030.448 per share and 2,097 shares at a weighted average price of $1,031.526 per share, in multiple transactions within narrow price ranges. Following these sales, Lilly Endowment Inc. beneficially owned 92,872,191 shares of Eli Lilly common stock, held directly.
Eli Lilly & Co. (LLY) disclosed that a major shareholder reported multiple open-market sales of common stock on 11/14/2025. The transactions, all coded as sales, included blocks of 103,871, 55,908, 17,567, and 949 shares at weighted average prices between $1,030.00 and $1,033.39 per share. After these trades, the reporting person directly beneficially owned 92,882,077 Eli Lilly shares. The prices reported reflect weighted averages for multiple trades within the stated price ranges.
Eli Lilly & Co (LLY) executive filed an initial statement of beneficial ownership. As of 11/07/2025, the reporting officer (EVP, President LLY Imm) directly owned 3,725 shares of common stock.
The filing also lists restricted stock units (each RSU equals one common share) covering 391 shares with dates 02/16/2026, 2,530 shares with dates 11/01/2026, 394 shares with dates 02/16/2027, and 354.091 shares with dates 02/16/2028. Ownership is reported as direct.
Eli Lilly (LLY) reported insider sales on a Form 4. On 11/13/2025, the reporting person sold 45,246 shares of common stock at a weighted average price of $1,030.21, and 1,360 shares at a weighted average price of $1,031.777. The filing notes these were executed in multiple trades within the stated price ranges. Following the transactions, the reporting person beneficially owned 93,060,372 shares.
Eli Lilly (LLY) reported an insider transaction: the company’s SVP, Finance, & CAO sold 1,000 shares of common stock at $1,010.50 per share on November 13, 2025 (transaction code S).
The filing states the trade was made under a Rule 10b5-1 trading plan adopted on November 20, 2024. Following the sale, the reporting person beneficially owns 2,839.659 shares directly and 1,727.9 shares indirectly through a 401(k).
Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.
Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.